We report data from the testing of our novel PDE8A – C-Raf disrupter/HOXD12 conjugate (from here on, named PPL-008) in MM415, a B-Raf inhibitor resistant malignant melanoma cell line (MM415; BRAF wt, KRAS wt, NRAS Q61L) and in an MM415 melanoma murine xenograft model. Here, NRAS is linked to melanoma.